2019 Shaffer Research Grants
For information about Shaffer Grants and research reports prior to 2013, please contact Glaucoma Research Foundation.
Spacing: small
Spacing: small
![2019 Shaffer Research Grants 1 Steven Barnes, Phd](https://glaucoma.org/wp-content/uploads/2024/02/2019-template-150x200_0003_steven-barnes.webp)
Steven Barnes, PhD
Doheny Eye Institute
Funded by Roberta and Robert H. Feldman
Project: Functional Resilience of Retinal Ganglion Cells During Mitochondrial Dysfunction
Summary: The production of energy in retinal ganglion cells is accompanied by metabolic byproducts, many of which are damaging to cellular function.
![2019 Shaffer Research Grants 2 Adnan Dibas, Phd](https://glaucoma.org/wp-content/uploads/2024/02/2019-template-150x200_0002_adnan-dibas.webp)
Adnan Dibas, PhD
North Texas Eye Research Institute
Funded by The Edward Joseph Daly Foundation
Project: Endothelin Converting Enzyme Knockdown is Neuroprotective in Glaucomatous Neuropathy
Summary: Very little is known about how and why the optic nerve is progressively damaged in glaucoma.
![2019 Shaffer Research Grants 3 Daniel M. Lipinski, Phd](https://glaucoma.org/wp-content/uploads/2024/02/2019-template-150x200_0004_daniel-lipinski.webp)
Daniel M. Lipinski, PhD
Medical College of Wisconsin
Funded by The Frank Stein and Paul S. May Grants for Innovative Glaucoma Research
Project: Development of rAAV Vector Technologies to Facilitate Topical Gene Delivery to the Cornea
Summary: New genetic material can be delivered to cells of the cornea via injection of a viral vector into in to the front chamber of the eye.
![2019 Shaffer Research Grants 4 Biraj Mahato, Phd](https://glaucoma.org/wp-content/uploads/2024/02/2019-template-150x200_0007_biraj-mahato-new.webp)
Biraj Mahato, PhD
University of North Texas Health Science Center
Funded by The Frank Stein and Paul S. May Grants for Innovative Glaucoma Research
Project: Chemically Reprogrammed Retinal Ganglion Cell Therapy to Treat Glaucomatous Neuropathy
Summary: Retinal ganglion cell (RGC) death is the hallmark for glaucomatous damage leading to irreversible vision loss and no curative treatments are available.
![2019 Shaffer Research Grants 5 Pierre Mattar, Msc, Phd](https://glaucoma.org/wp-content/uploads/2024/02/2019-template-150x200_0006_pierre-mattar.webp)
Pierre Mattar, MSc, PhD
Ottawa Hospital Research Institute
Funded by Carolyn and Richard Sloane
Project: Programming and Reprogramming for Retinal Ganglion Cell Replacement Therapy
Summary: Although glaucoma is frequently treatable with medication or surgery, a large proportion of afflicted individuals are diagnosed too late to prevent the death of key retinal neurons, which are called retinal ganglion cells (RGCs).
![2019 Shaffer Research Grants 6 Lauren Katie Wareham, Phd](https://glaucoma.org/wp-content/uploads/2024/02/2019-template-150x200_0005_lauren-k.-wareham.webp)
Lauren Katie Wareham, PhD
Vanderbilt University Medical Center
Funded by Dr. James and Elizabeth Wise
Project: Investigating the Role of the NO-GC-1-cGMP Signaling Pathway in Glaucoma
Summary: The GC1 murine model of glaucoma aligns well with the pathophysiology seen in primary open angle glaucoma patients; the disease progresses with age, and mice have moderately elevated IOP, leading to degeneration of the optic nerve.
![2019 Shaffer Research Grants 7 Pete A. Williams, Phd](https://glaucoma.org/wp-content/uploads/2024/02/2019-template-150x200_0000_pete-williams.webp)
Pete A. Williams, PhD
Karolinska Institutet
Funded by The Dr. Henry A. Sutro Family Grant for Research
Project: Targeting Neuronal Mitochondria for Neuroprotection in Glaucoma
Summary: Current glaucoma treatment strategies only target IOP, the principal treatable risk factor.